Oppenheimer raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $7 and keeps an Outperform rating on the shares following quarterly results. The firm cites outlook for continued commercial execution and sustainable growth.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: